Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01307397
Registration number
NCT01307397
Ethics application status
Date submitted
17/02/2011
Date registered
2/03/2011
Date last updated
18/12/2017
Titles & IDs
Public title
A Study of Vemurafenib in Participants With Metastatic Melanoma
Query!
Scientific title
An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma
Query!
Secondary ID [1]
0
0
2010-023526-21
Query!
Secondary ID [2]
0
0
MO25515
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malignant Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Vemurafenib
Experimental: Vemurafenib - Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
Treatment: Drugs: Vemurafenib
Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0
Query!
Assessment method [1]
0
0
The intensity of AEs were graded on a 5-point scale (Grade 1 to 5) according to the NCI-CTCAE version 4.0, where Grade 1 indicates "Mild" severity and Grade 5 indicates "Death". The CTCAE defines Grades 3 and 4 as follows: Grade 3 means "Severe"; Inability to work or perform normal daily activity; treatment or medical intervention is indicated in order to improve the overall well-being or symptoms; delaying the onset of treatment is not putting the survival of the participant at direct risk. Grade 4 means "Life-threatening, Disabling"; based on extreme limitation in activity; significant medical intervention/therapy required; and hospitalization probable.
Query!
Timepoint [1]
0
0
Baseline up to 28 days post end of treatment (maximum up to 46 months)
Query!
Primary outcome [2]
0
0
Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug Discontinuation
Query!
Assessment method [2]
0
0
An AE was considered as any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Pre existing conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. Percentage of participants with dose interruption or discontinuation due to AE was presented.
Query!
Timepoint [2]
0
0
Baseline up to 28 days post end of treatment (maximum up to 46 months)
Query!
Primary outcome [3]
0
0
Percentage of Participants With AEs of Special Interest
Query!
Assessment method [3]
0
0
AEs of special interest included cutaneous squamous cell carcinoma (SCC), rash, photosensitivity, liver injury, arthralgia, fatigue, gastrointestinal (GI) polyps, pancreatitis, potentiation of radiation toxicity, prolongation of cardiac repolarization or arrhythmia, non-cutaneous SCC and other primary malignancies (other than cutaneous SCC or new primary melanoma).
Query!
Timepoint [3]
0
0
Baseline up to 28 days post end of treatment (maximum up to 46 months)
Query!
Primary outcome [4]
0
0
Mean Cumulative Dose of Vemurafenib
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline up to end of treatment or death (maximum up to 46 months)
Query!
Primary outcome [5]
0
0
Duration of Vemurafenib Treatment
Query!
Assessment method [5]
0
0
Exposure excluding treatment interruptions: Duration during which participants actually took vemurafenib. Any time without dose-taken due to adverse events, non-compliance or any other reasons was not counted.
Exposure including treatment interruptions: date of last dose - date of first dose + 1; duration during which participants actually took vemurafenib as well as duration on which medication was not taken were included in this calculation.
Query!
Timepoint [5]
0
0
Baseline up to end of treatment or death (maximum upto 46 months)
Query!
Primary outcome [6]
0
0
Mean Total Vemurafenib Dose Per Day
Query!
Assessment method [6]
0
0
Exposure excluding treatment interruptions: Duration during which participants actually took vemurafenib. Any time without dose-taken due to adverse events, non-compliance or any other reasons was not counted.
Exposure including treatment interruptions: date of last dose - date of first dose + 1; duration during which participants actually took vemurafenib as well as duration on which medication was not taken were included in this calculation. Average total dose per day: total actual dose taken divided by total actual days on treatment.
Query!
Timepoint [6]
0
0
Baseline up to end of treatment or death (maximum up to 46 months)
Query!
Primary outcome [7]
0
0
Dose Intensity of Vemurafenib
Query!
Assessment method [7]
0
0
Dose intensity was defined as (total actual doses taken/total planned doses) \*100, where total planned doses = prescribed doses \* planned days on treatment, where planned days on treatment were defined as the interval between date of first dose and date of last dose.
Query!
Timepoint [7]
0
0
Baseline up to end of treatment or death (maximum upto 46 months)
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Improvement in Eastern Cooperative Group (ECOG) Performance Status
Query!
Assessment method [1]
0
0
ECOG Performance Status was measured on-therapy assessed participant's performance status on 5 point scale: 0 = fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than \[\>\] 50% of waking hours \[hrs\]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. Percentage of participants who had at least one point improvement from baseline at any assessment visit as well as at last study visit was reported.
Query!
Timepoint [1]
0
0
Baseline, Day 1 of each 28 day cycle up to end of treatment (up to 46 months)
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Received Any Concomitant Medications
Query!
Assessment method [2]
0
0
Concomitant medications were all medications taken during the study, including those started before but ongoing at first dose. No medications for Melanoma were included. Percentage of participants who received at least one concomitant medication was reported.
Query!
Timepoint [2]
0
0
Baseline up to 46 months
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR), as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Query!
Assessment method [3]
0
0
BOR was assessed by the investigator according to RECIST v1.1. BOR was defined as having confirmed CR or PR. CR: disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to less than (\<) 10 millimeter (mm) in short axis; PR: at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions.
Confirmed responses were those that persisted on repeat imaging greater than or equal to (\>=) 4 weeks after initial response.
Query!
Timepoint [3]
0
0
Baseline until first documentation of confirmed CR or PR (assessed at baseline, at Weeks 8, 16, as per institution standard of care thereafter but a minimum every 16 weeks thereafter until the end of the study [up to 46 months])
Query!
Secondary outcome [4]
0
0
Duration of Response
Query!
Assessment method [4]
0
0
The duration of response was defined as the time between the date of first confirmed CR or PR and date of first progression of disease (PD), or death, from any cause. Responses were assessed as per RECIST v1.1. CR: disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \< 10 mm in short axis; PR: at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions. Confirmed responses were those that persisted on repeat imaging \>= 4 weeks after initial response. PD: at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesion.
Query!
Timepoint [4]
0
0
From 1st documentation of confirmed CR or PR to PD or death, whichever occurred first (assessed at baseline, at Weeks 8, 16, as per institution standard of care thereafter but a minimum every 16 weeks thereafter until end of the study [up to 46 months])
Query!
Secondary outcome [5]
0
0
Time to Response
Query!
Assessment method [5]
0
0
Time to response was defined as the time between the date of first treatment and date of first confirmed CR or PR (assessed as per RECIST v1.1). CR: disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \< 10 mm in short axis; PR: at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions. Confirmed responses were those that persisted on repeat imaging \>= 4 weeks after initial response.
Query!
Timepoint [5]
0
0
Baseline until first documentation of confirmed CR or PR, whichever occurred first (assessed at baseline, at Weeks 8, 16, as per institution standard of care thereafter but a minimum every 16 weeks thereafter until the end of the study [up to 46 months])
Query!
Secondary outcome [6]
0
0
Percentage of Participants With PD Assessed According to RECIST v1.1 or Death
Query!
Assessment method [6]
0
0
PD was assessed according to RECIST v1.1. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesion.
Query!
Timepoint [6]
0
0
Baseline until PD or death, whichever occurred first (assessed at baseline, at Weeks 8, 16, as per institution standard of care thereafter but a minimum every 16 weeks thereafter until the end of the study [up to 46 months])
Query!
Secondary outcome [7]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [7]
0
0
PFS was defined as the time between the date of the first treatment and the date of first progression or death from any cause. PD was assessed according to RECIST v1.1. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesion.
Query!
Timepoint [7]
0
0
Baseline until PD or death, whichever occurred first (assessed at baseline, at Weeks 8, 16, as per institution standard of care thereafter but a minimum every 16 weeks thereafter until the end of the study [up to 46 months])
Query!
Secondary outcome [8]
0
0
Percentage of Participants Who Died
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline until death (maximum up to 46 months)
Query!
Secondary outcome [9]
0
0
Overall Survival (OS)
Query!
Assessment method [9]
0
0
Overall Survival was defined as the time from the date of first treatment to the date of death, regardless of the cause of death.
Query!
Timepoint [9]
0
0
Baseline until death (maximum up to 46 months)
Query!
Eligibility
Key inclusion criteria
* Participants with Histologically confirmed metastatic melanoma (surgically incurable and unresectable Stage IIIC or Stage IV; AJCC) with BRAF V 600 mutation determined by Cobas 4800 BRAF Mutation Test. Unresectable Stage IIIC disease must have had confirmation from a surgical oncologist
* Participants with either measurable or non-measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1
* Participants may or may not have received prior systemic therapy for metastatic melanoma
* Eastern Cooperative Oncology Group (ECOG) performance status between 0 to 2
* Adequate hematologic, renal and liver function
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Evidence of symptomatic central nervous system (CNS) lesions, use of steroids or anti-seizure medications for treatment of brain metastases prior to the first administration of vemurafenib
* Previous malignancy (other than melanoma) within the past 2 years, except for treated and controlled basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix
* Concurrent administration of any anti-cancer therapies other than those administered in the study
* Clinically significant cardiovascular disease or event within the 6 months prior to first administration of study drug
* Refractory nausea or vomiting, external biliary shunt, or significant bowel resection that would preclude adequate absorption
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/02/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
3219
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Melanoma Institute Australia - North Sydney
Query!
Recruitment hospital [2]
0
0
Newcastle Mater Misericordiae Hospital; Oncology - Waratah
Query!
Recruitment hospital [3]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [4]
0
0
Border Medical Oncology - Wodonga
Query!
Recruitment hospital [5]
0
0
Greenslopes Private Hospital; Gallipoli Research Centre - Greenslopes
Query!
Recruitment hospital [6]
0
0
The Townsville Hospital; Townsville Cancer Centre - Townsville
Query!
Recruitment hospital [7]
0
0
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology - Woolloongabba
Query!
Recruitment hospital [8]
0
0
Royal Adelaide Hospital; Oncology - Adelaide
Query!
Recruitment hospital [9]
0
0
Geelong Hospital; Geelong Cardiology Practice - Geelong
Query!
Recruitment hospital [10]
0
0
Peter MacCallum Cancer Centre; Medical Oncology - Melbourne
Query!
Recruitment hospital [11]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [12]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2060 - North Sydney
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
3690 - Wodonga
Query!
Recruitment postcode(s) [5]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [6]
0
0
4812 - Townsville
Query!
Recruitment postcode(s) [7]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [8]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [9]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [10]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [11]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [12]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
Albania
Query!
State/province [1]
0
0
Tirana
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Buenos Aires
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Feldkirch
Query!
Country [4]
0
0
Austria
Query!
State/province [4]
0
0
Graz
Query!
Country [5]
0
0
Austria
Query!
State/province [5]
0
0
Innsbruck
Query!
Country [6]
0
0
Austria
Query!
State/province [6]
0
0
Linz
Query!
Country [7]
0
0
Austria
Query!
State/province [7]
0
0
Salzburg
Query!
Country [8]
0
0
Austria
Query!
State/province [8]
0
0
St. Pölten
Query!
Country [9]
0
0
Austria
Query!
State/province [9]
0
0
Wien
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Brussel
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Bruxelles
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Wilrijk
Query!
Country [13]
0
0
Bosnia and Herzegovina
Query!
State/province [13]
0
0
Banja Luka
Query!
Country [14]
0
0
Bosnia and Herzegovina
Query!
State/province [14]
0
0
Sarajevo
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
RJ
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
RS
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
SP
Query!
Country [18]
0
0
Bulgaria
Query!
State/province [18]
0
0
Plovdiv
Query!
Country [19]
0
0
Bulgaria
Query!
State/province [19]
0
0
Sofia
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Alberta
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
British Columbia
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Manitoba
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Nova Scotia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Colombia
Query!
State/province [26]
0
0
Bogota
Query!
Country [27]
0
0
Colombia
Query!
State/province [27]
0
0
Cali
Query!
Country [28]
0
0
Colombia
Query!
State/province [28]
0
0
Medellin-Antioquia
Query!
Country [29]
0
0
Croatia
Query!
State/province [29]
0
0
Zagreb
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Brno
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Hradec Kralove
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Olomouc
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Ostrava
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Praha
Query!
Country [35]
0
0
Denmark
Query!
State/province [35]
0
0
Aarhus C
Query!
Country [36]
0
0
Denmark
Query!
State/province [36]
0
0
Herlev
Query!
Country [37]
0
0
Denmark
Query!
State/province [37]
0
0
Odense
Query!
Country [38]
0
0
Ecuador
Query!
State/province [38]
0
0
Cuenca
Query!
Country [39]
0
0
Ecuador
Query!
State/province [39]
0
0
Guayaquil
Query!
Country [40]
0
0
Ecuador
Query!
State/province [40]
0
0
Portoviejo
Query!
Country [41]
0
0
Estonia
Query!
State/province [41]
0
0
Tallinn
Query!
Country [42]
0
0
Estonia
Query!
State/province [42]
0
0
Tartu
Query!
Country [43]
0
0
Finland
Query!
State/province [43]
0
0
Helsinki
Query!
Country [44]
0
0
Finland
Query!
State/province [44]
0
0
Tampere
Query!
Country [45]
0
0
Finland
Query!
State/province [45]
0
0
Turku
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Aachen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Augsburg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Berlin
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Bochum
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Buxtehude
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Chemnitz
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Dresden
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Düsseldorf
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Erfurt
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Erlangen
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Essen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Frankfurt
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Freiburg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Gera
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Göttingen
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Hamburg
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Hannover
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Heidelberg
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Heilbronn
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Jena
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Kassel
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Kiel
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Köln
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Leipzig
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Ludwigshafen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Lübeck
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Magdeburg
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Mainz
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Mannheim
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Marburg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Minden
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
München
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Münster
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Nürnberg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Quedlinburg
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Recklinghausen
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Regensburg
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Tübingen
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Wiesbaden
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Wuppertal
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Würzburg
Query!
Country [87]
0
0
Greece
Query!
State/province [87]
0
0
Athens
Query!
Country [88]
0
0
Greece
Query!
State/province [88]
0
0
Heraklion
Query!
Country [89]
0
0
Greece
Query!
State/province [89]
0
0
Piraeus
Query!
Country [90]
0
0
Hungary
Query!
State/province [90]
0
0
Budapest
Query!
Country [91]
0
0
Hungary
Query!
State/province [91]
0
0
Debrecen
Query!
Country [92]
0
0
Hungary
Query!
State/province [92]
0
0
Pecs
Query!
Country [93]
0
0
Hungary
Query!
State/province [93]
0
0
Szeged
Query!
Country [94]
0
0
India
Query!
State/province [94]
0
0
Delhi
Query!
Country [95]
0
0
India
Query!
State/province [95]
0
0
Maharashtra
Query!
Country [96]
0
0
India
Query!
State/province [96]
0
0
Hyderabad
Query!
Country [97]
0
0
India
Query!
State/province [97]
0
0
Lucknow
Query!
Country [98]
0
0
India
Query!
State/province [98]
0
0
Trivandrum
Query!
Country [99]
0
0
India
Query!
State/province [99]
0
0
Vellore
Query!
Country [100]
0
0
Ireland
Query!
State/province [100]
0
0
Cork
Query!
Country [101]
0
0
Ireland
Query!
State/province [101]
0
0
Dublin
Query!
Country [102]
0
0
Ireland
Query!
State/province [102]
0
0
Galway
Query!
Country [103]
0
0
Ireland
Query!
State/province [103]
0
0
Limerick
Query!
Country [104]
0
0
Ireland
Query!
State/province [104]
0
0
Waterford
Query!
Country [105]
0
0
Israel
Query!
State/province [105]
0
0
Beer Sheva
Query!
Country [106]
0
0
Israel
Query!
State/province [106]
0
0
Hafia
Query!
Country [107]
0
0
Israel
Query!
State/province [107]
0
0
Jerusalem
Query!
Country [108]
0
0
Israel
Query!
State/province [108]
0
0
Ramat Gan
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Campania
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Emilia-Romagna
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Friuli-Venezia Giulia
Query!
Country [112]
0
0
Italy
Query!
State/province [112]
0
0
Lazio
Query!
Country [113]
0
0
Italy
Query!
State/province [113]
0
0
Liguria
Query!
Country [114]
0
0
Italy
Query!
State/province [114]
0
0
Lombardia
Query!
Country [115]
0
0
Italy
Query!
State/province [115]
0
0
Piemonte
Query!
Country [116]
0
0
Italy
Query!
State/province [116]
0
0
Puglia
Query!
Country [117]
0
0
Italy
Query!
State/province [117]
0
0
Sicilia
Query!
Country [118]
0
0
Italy
Query!
State/province [118]
0
0
Toscana
Query!
Country [119]
0
0
Italy
Query!
State/province [119]
0
0
Umbria
Query!
Country [120]
0
0
Italy
Query!
State/province [120]
0
0
Veneto
Query!
Country [121]
0
0
Korea, Republic of
Query!
State/province [121]
0
0
Seoul
Query!
Country [122]
0
0
Latvia
Query!
State/province [122]
0
0
Daugavpils
Query!
Country [123]
0
0
Latvia
Query!
State/province [123]
0
0
Riga
Query!
Country [124]
0
0
Lithuania
Query!
State/province [124]
0
0
Klaipeda
Query!
Country [125]
0
0
Lithuania
Query!
State/province [125]
0
0
Vilnius
Query!
Country [126]
0
0
Macedonia, The Former Yugoslav Republic of
Query!
State/province [126]
0
0
Skopje
Query!
Country [127]
0
0
Mexico
Query!
State/province [127]
0
0
Leon
Query!
Country [128]
0
0
Mexico
Query!
State/province [128]
0
0
Mexico City
Query!
Country [129]
0
0
Mexico
Query!
State/province [129]
0
0
Mexico DF
Query!
Country [130]
0
0
Netherlands
Query!
State/province [130]
0
0
Amsterdam
Query!
Country [131]
0
0
Netherlands
Query!
State/province [131]
0
0
Blaricum
Query!
Country [132]
0
0
Netherlands
Query!
State/province [132]
0
0
Breda
Query!
Country [133]
0
0
Netherlands
Query!
State/province [133]
0
0
Groningen
Query!
Country [134]
0
0
Netherlands
Query!
State/province [134]
0
0
Leiden
Query!
Country [135]
0
0
Netherlands
Query!
State/province [135]
0
0
Maastricht
Query!
Country [136]
0
0
Netherlands
Query!
State/province [136]
0
0
Nijmegen
Query!
Country [137]
0
0
Netherlands
Query!
State/province [137]
0
0
Rotterdam
Query!
Country [138]
0
0
Netherlands
Query!
State/province [138]
0
0
Utrecht
Query!
Country [139]
0
0
Norway
Query!
State/province [139]
0
0
Bergen
Query!
Country [140]
0
0
Norway
Query!
State/province [140]
0
0
Oslo
Query!
Country [141]
0
0
Peru
Query!
State/province [141]
0
0
Arequipa
Query!
Country [142]
0
0
Peru
Query!
State/province [142]
0
0
Lima
Query!
Country [143]
0
0
Poland
Query!
State/province [143]
0
0
Krakow
Query!
Country [144]
0
0
Poland
Query!
State/province [144]
0
0
Olsztyn
Query!
Country [145]
0
0
Poland
Query!
State/province [145]
0
0
Poznan
Query!
Country [146]
0
0
Poland
Query!
State/province [146]
0
0
Warszawa
Query!
Country [147]
0
0
Portugal
Query!
State/province [147]
0
0
Lisboa
Query!
Country [148]
0
0
Portugal
Query!
State/province [148]
0
0
Porto
Query!
Country [149]
0
0
Romania
Query!
State/province [149]
0
0
Bucuresti
Query!
Country [150]
0
0
Romania
Query!
State/province [150]
0
0
Cluj-Napoca
Query!
Country [151]
0
0
Romania
Query!
State/province [151]
0
0
Timisoara
Query!
Country [152]
0
0
Russian Federation
Query!
State/province [152]
0
0
Leningrad
Query!
Country [153]
0
0
Russian Federation
Query!
State/province [153]
0
0
Krasnodar
Query!
Country [154]
0
0
Russian Federation
Query!
State/province [154]
0
0
Moscow
Query!
Country [155]
0
0
Russian Federation
Query!
State/province [155]
0
0
Saint-Petersburg
Query!
Country [156]
0
0
Russian Federation
Query!
State/province [156]
0
0
Stavropol
Query!
Country [157]
0
0
Russian Federation
Query!
State/province [157]
0
0
UFA
Query!
Country [158]
0
0
Serbia
Query!
State/province [158]
0
0
Belgrade
Query!
Country [159]
0
0
Slovakia
Query!
State/province [159]
0
0
Bratislava
Query!
Country [160]
0
0
Slovakia
Query!
State/province [160]
0
0
Poprad
Query!
Country [161]
0
0
Slovenia
Query!
State/province [161]
0
0
Ljubljana
Query!
Country [162]
0
0
South Africa
Query!
State/province [162]
0
0
Bloemfontein
Query!
Country [163]
0
0
South Africa
Query!
State/province [163]
0
0
Cape Town
Query!
Country [164]
0
0
South Africa
Query!
State/province [164]
0
0
Johannesburg
Query!
Country [165]
0
0
South Africa
Query!
State/province [165]
0
0
Pretoria
Query!
Country [166]
0
0
South Africa
Query!
State/province [166]
0
0
Sandton
Query!
Country [167]
0
0
Spain
Query!
State/province [167]
0
0
Asturias
Query!
Country [168]
0
0
Spain
Query!
State/province [168]
0
0
Cantabria
Query!
Country [169]
0
0
Spain
Query!
State/province [169]
0
0
Islas Baleares
Query!
Country [170]
0
0
Spain
Query!
State/province [170]
0
0
Las Palmas
Query!
Country [171]
0
0
Spain
Query!
State/province [171]
0
0
Murcia
Query!
Country [172]
0
0
Spain
Query!
State/province [172]
0
0
Navarra
Query!
Country [173]
0
0
Spain
Query!
State/province [173]
0
0
Pontevedra
Query!
Country [174]
0
0
Spain
Query!
State/province [174]
0
0
Tenerife
Query!
Country [175]
0
0
Spain
Query!
State/province [175]
0
0
Vizcaya
Query!
Country [176]
0
0
Spain
Query!
State/province [176]
0
0
Barcelona
Query!
Country [177]
0
0
Spain
Query!
State/province [177]
0
0
Cordoba
Query!
Country [178]
0
0
Spain
Query!
State/province [178]
0
0
Granada
Query!
Country [179]
0
0
Spain
Query!
State/province [179]
0
0
La Coruña
Query!
Country [180]
0
0
Spain
Query!
State/province [180]
0
0
Leon
Query!
Country [181]
0
0
Spain
Query!
State/province [181]
0
0
Madrid
Query!
Country [182]
0
0
Spain
Query!
State/province [182]
0
0
Malaga
Query!
Country [183]
0
0
Spain
Query!
State/province [183]
0
0
Salamanca
Query!
Country [184]
0
0
Spain
Query!
State/province [184]
0
0
Sevilla
Query!
Country [185]
0
0
Spain
Query!
State/province [185]
0
0
Valencia
Query!
Country [186]
0
0
Spain
Query!
State/province [186]
0
0
Zaragoza
Query!
Country [187]
0
0
Sweden
Query!
State/province [187]
0
0
Gothenburg
Query!
Country [188]
0
0
Sweden
Query!
State/province [188]
0
0
Lund
Query!
Country [189]
0
0
Sweden
Query!
State/province [189]
0
0
Stockholm
Query!
Country [190]
0
0
Sweden
Query!
State/province [190]
0
0
Umeå
Query!
Country [191]
0
0
Sweden
Query!
State/province [191]
0
0
Uppsala
Query!
Country [192]
0
0
Switzerland
Query!
State/province [192]
0
0
Basel
Query!
Country [193]
0
0
Switzerland
Query!
State/province [193]
0
0
Bern
Query!
Country [194]
0
0
Switzerland
Query!
State/province [194]
0
0
Chur
Query!
Country [195]
0
0
Switzerland
Query!
State/province [195]
0
0
Lausanne
Query!
Country [196]
0
0
Switzerland
Query!
State/province [196]
0
0
St. Gallen
Query!
Country [197]
0
0
Switzerland
Query!
State/province [197]
0
0
Zürich
Query!
Country [198]
0
0
Turkey
Query!
State/province [198]
0
0
Adana
Query!
Country [199]
0
0
Turkey
Query!
State/province [199]
0
0
Ankara
Query!
Country [200]
0
0
Turkey
Query!
State/province [200]
0
0
Antalya
Query!
Country [201]
0
0
Turkey
Query!
State/province [201]
0
0
Bornova, IZMIR
Query!
Country [202]
0
0
Turkey
Query!
State/province [202]
0
0
Gaziantep
Query!
Country [203]
0
0
Turkey
Query!
State/province [203]
0
0
Istanbul
Query!
Country [204]
0
0
Turkey
Query!
State/province [204]
0
0
Izmir
Query!
Country [205]
0
0
Turkey
Query!
State/province [205]
0
0
Sihhiye, ANKARA
Query!
Country [206]
0
0
United Kingdom
Query!
State/province [206]
0
0
Cambridge
Query!
Country [207]
0
0
United Kingdom
Query!
State/province [207]
0
0
Glasgow
Query!
Country [208]
0
0
United Kingdom
Query!
State/province [208]
0
0
Guildford
Query!
Country [209]
0
0
United Kingdom
Query!
State/province [209]
0
0
Leeds
Query!
Country [210]
0
0
United Kingdom
Query!
State/province [210]
0
0
London
Query!
Country [211]
0
0
United Kingdom
Query!
State/province [211]
0
0
Manchester
Query!
Country [212]
0
0
United Kingdom
Query!
State/province [212]
0
0
Newcastle upon Tyne
Query!
Country [213]
0
0
United Kingdom
Query!
State/province [213]
0
0
Northwood
Query!
Country [214]
0
0
United Kingdom
Query!
State/province [214]
0
0
Nottingham
Query!
Country [215]
0
0
United Kingdom
Query!
State/province [215]
0
0
Oxford
Query!
Country [216]
0
0
United Kingdom
Query!
State/province [216]
0
0
Southampton
Query!
Country [217]
0
0
United Kingdom
Query!
State/province [217]
0
0
Swansea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer \[AJCC\]) metastatic melanoma.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01307397
Query!
Trial related presentations / publications
Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandala M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C. An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandala M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01307397
Download to PDF